Edition:
United Kingdom

Gensight Biologics SA (SIGHT.PA)

SIGHT.PA on Paris Stock Exchange

1.97EUR
22 Mar 2019
Change (% chg)

€-0.08 (-3.90%)
Prev Close
€2.05
Open
€2.06
Day's High
€2.11
Day's Low
€1.89
Volume
475,245
Avg. Vol
369,130
52-wk High
€6.18
52-wk Low
€1.34

Latest Key Developments (Source: Significant Developments)

Gensight Biologics Completes Capital Increase Of 8 Million Euros Subscribed Entirely By Sofinnova
Monday, 25 Feb 2019 

Feb 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS COMPLETES A CAPITAL INCREASE OF €8 MILLION WITHOUT DISCOUNT SUBSCRIBED ENTIRELY BY SOFINNOVA.THIS CAPITAL INCREASE IS TO PURSUE FINAL STAGES OF CLINICAL DEVELOPMENT OF GS010, AND FILE FOR MARKETING AUTHORIZATION IN EUROPE.NEW SHARES WITH NOMINAL VALUE OF EUR 0.025 EACH FOR SUBSCRIPTION PRICE OF EUR 2.04 EACH (INCLUDING PREMIUM).CAPITAL INCREASE WOULD IMPROVE FINANCIAL HORIZON FOR COMPANY AND DRIVE IT FROM Q3 OF 2019 TO Q2 OF 2020.  Full Article

GenSight Biologics Reports Results At Week 48 Of The Rescue Phase III Clinical Trial Of GS010
Monday, 4 Feb 2019 

Feb 4 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS TOPLINE RESULTS AT WEEK 48 OF THE RESCUE PHASE III CLINICAL TRIAL OF GS010 IN SUBJECTS WITHIN SIX MONTHS OF VISUAL LOSS ONSET DUE TO LEBER HEREDITARY OPTIC NEUROPATHY (LHON).STATISTICAL ANALYSIS SUGGESTS THAT AT WEEK 48, GS010-TREATED EYES WERE THREE TIMES MORE LIKELY THAN SHAM-TREATED EYES TO HAVE A LEVEL OF VISION OF 20/200 OR BETTER, THRESHOLD FOR LEGAL BLINDNESS.1 IN 4 SUBJECTS SHOWED BETTER BCVA FROM BASELINE IN THEIR GS010-TREATED EYE THAN IN THEIR SHAM-TREATED EYE (AT LEAST 0.3 LOGMAR OR 15 ETDRS LETTERS, A CLINICALLY MEANINGFUL DIFFERENCE).1 IN 4 SUBJECTS SHOWED BETTER CHANGE IN LOW-CONTRAST SENSITIVITY IN THEIR GS010-TREATED EYE THAN IN THEIR SHAM-TREATED EYE (AT LEAST 0.3 LOGCS, A CLINICALLY MEANINGFUL DIFFERENCE).GS010 REPORTED TO BE SAFE AND WELL-TOLERATED.ANATOMIC MEASURES SHOWED RESULTS BROADLY CONSISTENT WITH DIRECTION OF BCVA EVOLUTION.  Full Article

Gensight Biologics Reports Data in Phase III Reverse Clinical Trial Of GS010
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS SUSTAINED QUALITY OF LIFE IMPROVEMENTS AT WEEK 72 OF PHASE III REVERSE CLINICAL TRIAL OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON).TOPLINE 48-WEEK DATA FOR RESCUE, SECOND PHASE III CLINICAL TRIAL OF GS010 IN TREATMENT OF LHON, IS EXPECTED IN EARLY Q1 2019.REVERSE SUBJECTS WILL BE EVALUATED AGAIN AT 96 WEEKS, AND DATA WILL BE REPORTED IN Q2 OF 2019.  Full Article

Gensight Biologics H1 Net Loss Widens To 11.7 Million Euros
Wednesday, 25 Jul 2018 

July 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS INTERIM FINANCIAL RESULTS FOR THE FIRST HALF OF 2018.H1 NET LOSS EUR 11.7 MILLION VERSUS LOSS OF EUR 10.1 MILLION YEAR AGO.OPERATING INCOME REMAINED STABLE OVER PERIOD, AMOUNTING TO EUR 2.0 MILLION IN H1 OF 2017 AND 2018.  Full Article

Gensight Biologics Reports Positive Results From Phase I/Ii Study Of Gs010
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS REPORTS POSITIVE LONG-TERM VISUAL ACUITY GAINS AND SAFETY RESULTS FROM PHASE I/II STUDY OF GS010 FOR THE TREATMENT OF LEBER HEREDITARY OPTIC NEUROPATHY (LHON).CONFIRMATION OF THE FAVORABLE LONG-TERM SAFETY PROFILE OF GS010‍​.SIGNIFICANT IMPROVEMENT OF VISUAL ACUITY AT 2.5 YEARS OF FOLLOW-UP IN CERTAIN LHON PATIENTS.LHON PATIENTS WITH LESS THAN 2 YEARS OF ONSET OF VISUAL LOSS PRIOR TO TREATMENT.  Full Article

Gensight Biologics: cash and cash equivalents position at Sept 30 at EUR 59.5​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - GENSIGHT BIOLOGICS SA : :‍CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 59.5 MILLION AS OF SEPTEMBER 30, 2017, COMPARED TO EUR 63.6 MILLION AS OF JUNE 30, 2017.​.  Full Article

Gensight Biologics appoints Barrett Katz as Chief Medical Officer
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GENSIGHT BIOLOGICS SA ::GENSIGHT BIOLOGICS APPOINTS BARRETT KATZ AS CHIEF MEDICAL OFFICER.  Full Article